Alemtuzumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00087 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 8 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hepatic infarction | KG + DL |
| 2 | syndrome with combined immunodeficiency | KG + DL |
| 3 | hepatic veno-occlusive disease | KG + DL |
| 4 | kidney pelvis sarcomatoid transitional cell carcinoma | KG + DL |
| 5 | infiltrating bladder urothelial carcinoma sarcomatoid variant | KG + DL |
| 6 | prostatic urethra urothelial carcinoma | KG + DL |
| 7 | renal pelvis papillary urothelial carcinoma | KG + DL |
| 8 | peliosis hepatis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.